Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionDeutsche Bank Ag\
Latest Disclosed Ownership761,464 shares
Latest Disclosed Value $ 251,945,593
Deutsche Bank Ag\ ownership in DUL / Alnylam Pharmaceuticals, Inc.

On May 6, 2026 - Deutsche Bank Ag\ filed a 13F-HR form disclosing ownership of 761,464 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $217,550,265 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 711,975 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 6.95% during the quarter. The current value of the position is $198,361,372 USD.

Deutsche Bank Ag\ has a history of taking positions in derivatives of the underlying security (DUL) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 10,400 of underlying shares valued at $3,441,048 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:DUL / Alnylam Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 761,464 49,489 6.95 251,946 -11.01 0.0832
2026-02-11 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 711,975 105,655 17.43 283,117 2.40 0.0922
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 606,320 -42,964 -6.62 276,482 30.58 0.0926
2025-08-12 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 649,284 72,291 12.53 211,725 35.90 0.0780
2025-05-09 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 576,993 20,414 3.67 155,800 18.96 0.0617
2025-06-30 2024-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 556,579 17,308 3.21 130,969 -11.70 0.0513
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 556,579 17,308 130,969 0.0511
2025-06-26 2024-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 539,271 50,153 10.25 148,316 24.79 0.0604
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 539,271 50,153 148,316 0.0604
2025-06-12 2024-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 489,118 -17,959 -3.54 118,856 56.84 0.0536
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 489,118 -17,959 118,856 0.0536
2025-06-02 2024-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 507,077 44,758 9.68 75,783 -14.36 0.0352
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 507,077 44,758 75,783 0.0352
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 462,319 -537 -0.12 88,492 7.96 0.0451
2023-11-24 2023-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 462,856 -24,020 -4.93 81,972 -11.36 0.0529
2023-11-09 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 462,856 -24,020 81,972 0.0453
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 486,876 27,310 5.94 92,477 0.45 0.0492
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 459,566 -5,487 -1.18 92,060 -16.70 0.0513
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 465,053 211,369 83.32 110,520 117.65 0.0636
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 253,684 6,437 2.60 50,778 40.81 0.0306
2022-08-11 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 247,247 -34,863 -12.36 36,061 -21.72 0.0201
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 282,110 7,462 2.72 46,066 -1.09 0.0215
2022-02-16 2021-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 274,648 -7,514 -2.66 46,574 -12.58 0.0209
2022-02-11 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 274,648 -7,514 46,574 0.0209
2021-11-04 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 282,162 17,319 6.54 53,275 18.66 0.0253
2021-08-11 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 264,843 6,261 2.42 44,896 22.97 0.0218
2021-05-13 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 258,582 -34,685 -11.83 36,510 -4.22 0.0197
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 293,267 5,761 2.00 38,117 -8.94 0.0233
2020-11-12 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 287,506 1,416 0.49 41,860 -1.21 0.0288
2020-08-13 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 286,090 -6,553 -2.24 42,372 33.02 0.0322
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 292,643 11,423 4.06 31,854 -1.64 0.0284
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 281,220 -374,410 -57.11 32,385 -38.58 0.0211
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 655,630 -100,511 -13.29 52,723 -3.90 0.0366
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 756,141 299,860 65.72 54,862 28.68 0.0322
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 456,281 256,013 127.84 42,635 192.06 0.0254
2019-04-01 2018-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 200,268 -104,328 -34.25 14,598 -45.24 0.0104
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 200,268 -37,901 14,598
2021-12-21 2018-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 304,596 -241,000 -44.17 26,658 -50.39 0.0135
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 238,169 -307,427 20,843 0.0144
2020-04-21 2018-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 545,596 98,936 22.15 53,736 1.02 0.0268
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 472,697 26,037 46,553 30,920.3866
2019-10-23 2018-03-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 446,660 235,543 111.57 53,193 98.34 0.0254
2019-10-18 2018-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 446,660 0 53,193 0.0254
2018-05-15 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 388,743 177,626 46,297
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 211,117 37,667 21.72 26,819 31.62 0.0172
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 173,450 -18,946 -9.85 20,376 32.81 0.0140
2017-08-11 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 192,396 -15,571 -7.49 15,342 43.98 0.0110
2017-05-15 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 207,967 -113,021 -35.21 10,656 -11.31 0.0079
2017-02-14 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 320,988 -75,236 -18.99 12,015 -55.26 0.0097
2016-11-14 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 396,224 3,473 0.88 26,853 23.24 0.0190
2016-08-15 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 392,751 90,056 29.75 21,790 14.70 0.0154
2016-05-16 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 302,695 36,449 13.69 18,998 -24.19 0.0143
2016-02-16 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 266,246 -112,568 -29.72 25,061 -17.66 0.0173
2015-11-17 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 378,814 -18,659 -4.69 30,437 -36.11 0.0235
2015-08-12 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 397,473 115,854 41.14 47,638 62.04 0.0304
2015-05-15 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 281,619 71,673 34.14 29,399 44.37 0.0183
2015-02-13 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 209,946 34,901 19.94 20,363 48.98 0.0126
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 175,045 7,006 4.17 13,668 28.80 0.0085
2014-08-15 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 168,039 -86,932 -34.09 10,612 -38.00 0.0072
2014-05-15 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 254,971 141,215 124.14 17,116 134.05 0.0122
2014-02-24 2013-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 113,756 -52,993 -31.78 7,313 -31.47 0.0053
2014-02-18 2013-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 113,756 7,313
2013-11-18 2013-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 166,749 68,198 69.20 10,672 249.56 0.0079
2013-08-16 2013-06-30 13F ALNYLAM PHARMACEUTICALS COM 002043Q10 98,551 98,551 3,053 0.0025
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-05-09 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-06-30 2024-12-31 13F/A ALNYLAM PHARMACEUTICALS COM Call 3,200 753 n/a n/a n/a
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 3,200 753 n/a n/a n/a
2025-06-26 2024-09-30 13F/A ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 0 0 n/a n/a n/a
2025-06-12 2024-06-30 13F/A ALNYLAM PHARMACEUTICALS COM Call 50,200 195.29 12,199 380.24 n/a n/a n/a
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 50,200 12,199 n/a n/a n/a
2025-06-02 2024-03-31 13F/A ALNYLAM PHARMACEUTICALS COM Call 17,000 -4.49 2,541 -25.45 n/a n/a n/a
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 17,000 2,541 n/a n/a n/a
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 17,800 3,407 n/a n/a n/a
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 50 10 n/a n/a n/a
2017-08-11 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2017-05-15 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 630 32 n/a n/a n/a
2015-05-15 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2015-02-13 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 80 7 n/a n/a n/a
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2014-08-15 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 575 -52.08 36 500.00 n/a n/a n/a
2014-05-15 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 1,200 33.33 6 -50.00 n/a n/a n/a
2014-02-24 2013-12-31 13F/A ALNYLAM PHARMACEUTICALS COM Call 900 80.00 12 500.00 n/a n/a n/a
2014-02-18 2013-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 900 12 n/a n/a n/a
2013-11-18 2013-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2013-08-16 2013-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 500 2 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-06 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 10,400 0.00 3,441 -16.78 n/a n/a n/a
2026-02-11 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 10,400 26.83 4,136 10.59 n/a n/a n/a
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 8,200 3,739 n/a n/a n/a
2025-06-26 2024-09-30 13F/A ALNYLAM PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 0 0 n/a n/a n/a
2025-06-12 2024-06-30 13F/A ALNYLAM PHARMACEUTICALS COM Put 8,700 2,114 n/a n/a n/a
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 8,700 2,114 n/a n/a n/a
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2014-08-15 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 368 -63.20 23 475.00 n/a n/a n/a
2014-05-15 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 1,000 4 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.